Dachaigh › Lymphoma Burkitt › Maryland
Sgrùdaidhean clionaigeach Lymphoma Burkitt ann an Maryland
Tha 11 sgrùdaidhean airson Lymphoma Burkitt a’ lorg phàirtichean aig làraichean ann an Maryland.
Bailtean ann an Maryland
Teacsa sgrùdaidh oifigeil (Beurla)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
A’ fastadhÌre 2
366 Days – 46 Years · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Maryland/Greenebaum Cancer Center, Baltimore
A’ fastadhÌre 3
Aoisean 18 gu 39 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT03150693CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
A’ fastadhÌre 1/2
Aoisean 3 gu 39 · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT05442515Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
A’ fastadhÌre 1/2
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT03223610Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A’ fastadhÌre 2
365 Days · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Johns Hopkins Asthma & Allergy Center, Baltimore
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Sult 2026 · NCT07648264Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Maryland, Baltimore
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A’ fastadhÌre 2
Aoisean 1 gu 30 · Gach gnè · Air ùrachadh 1 Sult 2026 · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- National Institutes of Health Clinical Center, Bethesda
A’ fastadhÌre 1
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- agus 1 a bharrachd
A’ fastadhÌre 3
365 Days – 25 Years · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT03959085Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Maryland, Baltimore
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Samh 2025 · NCT04260022Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.